Rapid Determination of SARS-CoV-2 Integrity and Infectivity by Using Propidium Monoazide Coupled with Digital Droplet PCR
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25116156 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Giuseppe Sberna und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases "Lazzaro Spallanzani" (IRCCS), 00149 Rome, Italy. Hauptthemen laut MEDLINE: SARS-CoV-2, Azides, Propidium, COVID-19. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute, European Virus Archive - GLOBAL, Valentino s.p.a..
Abstract (Originalsprache)
SARS-CoV-2 is a highly infectious virus responsible for the COVID-19 pandemic. Therefore, it is important to assess the risk of SARS-CoV-2 infection, especially in persistently positive patients. Rapid discrimination between infectious and non-infectious viruses aids in determining whether prevention, control, and treatment measures are necessary. For this purpose, a method was developed and utilized involving a pre-treatment with 50 µM of propidium monoazide (PMAxx, a DNA intercalant) combined with a digital droplet PCR (ddPCR). The ddPCR method was performed on 40 nasopharyngeal swabs (NPSs) both before and after treatment with PMAxx, revealing a reduction in the viral load at a mean of 0.9 Log copies/mL (SD ± 0.6 Log copies/mL). Furthermore, six samples were stratified based on the Ct values of SARS-CoV-2 RNA (Ct < 20, 20 < Ct < 30, Ct > 30) and analyzed to compare the results obtained via a ddPCR with viral isolation and a negative-chain PCR. Of the five samples found positive via a ddPCR after the PMAxx treatment, two of the samples showed the highest post-treatment SARS-CoV-2 loads. The virus was isolated in vitro from both samples and the negative strand chains were detected. In three NPS samples, SARS CoV-2 was present post-treatment at a low level; it was not isolated in vitro, and, when detected, the strand was negative. Our results indicate that the established method is useful for determining whether the SARS-CoV-2 within positive NPS samples is intact and capable of causing infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases "Lazzaro Spallanzani" (IRCCS), 00149 Rome, Italy.
- Scientific Direction, National Institute for Infectious Diseases "Lazzaro Spallanzani" (IRCCS), 00149 Rome, Italy.
ORCID-Profile: Giuseppe Sberna, Giulia Matusali, Fabrizio Carletti, Enrico Girardi, Fabrizio Maggi
Förderung
- Ministero della Salute
- European Virus Archive - GLOBAL
- Valentino s.p.a.
- Italian Ministry of Health (Programme CCM 2020 Ricerca Corrente—Linea 1 on emerging and re-emerging infections)
- European Virus Archive—GLOBAL
- National Institute for Infectious Diseases “Lazzaro Spallanzani”, IRCCS
Zitieren
APA
Sberna, G., Mija, C., Lalle, E., Rozera, G., Matusali, G., Carletti, F., Girardi, E., & Maggi, F. (2024). Rapid Determination of SARS-CoV-2 Integrity and Infectivity by Using Propidium Monoazide Coupled with Digital Droplet PCR. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25116156
Vancouver
Sberna G, Mija C, Lalle E, Rozera G, Matusali G, Carletti F, et al. Rapid Determination of SARS-CoV-2 Integrity and Infectivity by Using Propidium Monoazide Coupled with Digital Droplet PCR. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25116156
BibTeX
@article{Sberna2024,
author = {Sberna, Giuseppe and Mija, Cosmina and Lalle, Eleonora and Rozera, Gabriella and Matusali, Giulia and Carletti, Fabrizio and Girardi, Enrico and Maggi, Fabrizio},
title = {Rapid Determination of SARS-CoV-2 Integrity and Infectivity by Using Propidium Monoazide Coupled with Digital Droplet PCR},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25116156}
}
EUVIMED